Market Closed -
NSE India S.E.
07:40:31 2024-06-11 am EDT
|
5-day change
|
1st Jan Change
|
586.3
INR
|
+2.74%
|
|
+14.07%
|
+38.16%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
80,373
|
49,034
|
19,118
|
45,869
|
37,972
|
22,175
|
Enterprise Value (EV)
1 |
105,423
|
78,805
|
52,659
|
69,944
|
56,132
|
42,855
|
P/E ratio
|
-13.2
x
|
-25.2
x
|
-27.6
x
|
6.68
x
|
-13
x
|
-3.97
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.05
x
|
1.18
x
|
0.67
x
|
1.69
x
|
1.18
x
|
0.84
x
|
EV / Revenue
|
2.69
x
|
1.9
x
|
1.85
x
|
2.58
x
|
1.74
x
|
1.62
x
|
EV / EBITDA
|
-173
x
|
61.6
x
|
169
x
|
-49.1
x
|
24.8
x
|
171
x
|
EV / FCF
|
-254
x
|
-25.7
x
|
61.8
x
|
-19.1
x
|
22.8
x
|
-90
x
|
FCF Yield
|
-0.39%
|
-3.89%
|
1.62%
|
-5.24%
|
4.39%
|
-1.11%
|
Price to Book
|
2.86
x
|
1.88
x
|
0.73
x
|
1.39
x
|
1
x
|
0.67
x
|
Nbr of stocks (in thousands)
|
110,630
|
110,686
|
110,735
|
110,781
|
144,053
|
144,088
|
Reference price
2 |
726.5
|
443.0
|
172.6
|
414.0
|
263.6
|
153.9
|
Announcement Date
|
8/5/18
|
7/17/19
|
7/5/20
|
7/8/21
|
7/20/22
|
7/21/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
39,245
|
41,584
|
28,440
|
27,083
|
32,300
|
26,510
|
EBITDA
1 |
-610.7
|
1,279
|
312
|
-1,425
|
2,260
|
250
|
EBIT
1 |
-2,050
|
-310.9
|
-1,264
|
-3,066
|
510
|
-1,500
|
Operating Margin
|
-5.22%
|
-0.75%
|
-4.44%
|
-11.32%
|
1.58%
|
-5.66%
|
Earnings before Tax (EBT)
1 |
-6,412
|
-3,003
|
-3,420
|
-5,683
|
-4,110
|
-6,240
|
Net income
1 |
-6,083
|
-1,945
|
-692.2
|
6,861
|
-2,440
|
-5,590
|
Net margin
|
-15.5%
|
-4.68%
|
-2.43%
|
25.33%
|
-7.55%
|
-21.09%
|
EPS
2 |
-55.01
|
-17.58
|
-6.252
|
61.95
|
-20.24
|
-38.80
|
Free Cash Flow
1 |
-414.7
|
-3,062
|
852.7
|
-3,666
|
2,466
|
-476.2
|
FCF margin
|
-1.06%
|
-7.36%
|
3%
|
-13.53%
|
7.64%
|
-1.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
273.29%
|
-
|
109.13%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/5/18
|
7/17/19
|
7/5/20
|
7/8/21
|
7/20/22
|
7/21/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
25,050
|
29,772
|
33,541
|
24,075
|
18,160
|
20,680
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-41.02
x
|
23.28
x
|
107.5
x
|
-16.9
x
|
8.035
x
|
82.72
x
|
Free Cash Flow
1 |
-415
|
-3,062
|
853
|
-3,666
|
2,466
|
-476
|
ROE (net income / shareholders' equity)
|
-19.3%
|
-6.99%
|
-4.55%
|
-8.7%
|
-7.01%
|
-15.8%
|
ROA (Net income/ Total Assets)
|
-1.49%
|
-0.24%
|
-0.99%
|
-2.4%
|
0.4%
|
-1.18%
|
Assets
1 |
408,009
|
800,865
|
70,210
|
-285,561
|
-613,065
|
474,815
|
Book Value Per Share
2 |
254.0
|
236.0
|
235.0
|
299.0
|
263.0
|
228.0
|
Cash Flow per Share
2 |
81.10
|
35.90
|
19.80
|
21.00
|
25.70
|
6.250
|
Capex
1 |
3,074
|
2,749
|
1,724
|
805
|
1,180
|
420
|
Capex / Sales
|
7.83%
|
6.61%
|
6.06%
|
2.97%
|
3.65%
|
1.58%
|
Announcement Date
|
8/5/18
|
7/17/19
|
7/5/20
|
7/8/21
|
7/20/22
|
7/21/23
|
|
1st Jan change
|
Capi.
|
---|
| +38.16% | 1.05B | | +19.08% | 43.46B | | +24.43% | 22.61B | | +16.33% | 15.15B | | +22.78% | 14.83B | | +57.41% | 13.08B | | -0.05% | 6.79B | | -12.44% | 6.72B | | -8.87% | 5.73B | | +12.71% | 5.45B |
Generic Pharmaceuticals
|